# Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients

> **NCT01335464** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 515 (actual)

## Conditions studied

- Pulmonary Fibrosis

## Interventions

- **DRUG:** placebo
- **DRUG:** BIBF 1120

## Key facts

- **NCT ID:** NCT01335464
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 515 (ACTUAL)
- **Last updated:** 2016-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01335464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01335464, "Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01335464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*